Thp-1 Luciferase M2 Polarization

MART-1 / Melan-A(M2-7C10 + M2-9E3) Antibody
BNCA0705-250 250uL
EUR 459.6
Description: Primary antibody against MART-1 / Melan-A(M2-7C10 + M2-9E3), APC conjugate, Concentration: 0.1mg/mL

Human IgG antibody Laboratories manufactures the thp-1 luciferase m2 polarization reagents distributed by Genprice. The Thp-1 Luciferase M2 Polarization reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact luciferase assay. Other Thp-1 products are available in stock. Specificity: Thp-1 Category: Luciferase Group: M2 Polarization

MART-1 / Melan-A(M2-7C10 + M2-9E3) Antibody
100uL
EUR 238.8
Description: Primary antibody against MART-1 / Melan-A(M2-7C10 + M2-9E3), CF488A conjugate, Concentration: 0.1mg/mL

MART-1 / Melan-A(M2-7C10 + M2-9E3) Antibody
500uL
EUR 652.8
Description: Primary antibody against MART-1 / Melan-A(M2-7C10 + M2-9E3), CF488A conjugate, Concentration: 0.1mg/mL

MART-1 / Melan-A(M2-7C10 + M2-9E3) Antibody
100uL
EUR 238.8
Description: Primary antibody against MART-1 / Melan-A(M2-7C10 + M2-9E3), CF405M conjugate, Concentration: 0.1mg/mL

MART-1 / Melan-A(M2-7C10 + M2-9E3) Antibody
500uL
EUR 652.8
Description: Primary antibody against MART-1 / Melan-A(M2-7C10 + M2-9E3), CF405M conjugate, Concentration: 0.1mg/mL

MART-1 / Melan-A(M2-7C10 + M2-9E3) Antibody
100uL
EUR 238.8
Description: Primary antibody against MART-1 / Melan-A(M2-7C10 + M2-9E3), CF405S conjugate, Concentration: 0.1mg/mL

MART-1 / Melan-A(M2-7C10 + M2-9E3) Antibody
500uL
EUR 652.8
Description: Primary antibody against MART-1 / Melan-A(M2-7C10 + M2-9E3), CF405S conjugate, Concentration: 0.1mg/mL

MART-1 / Melan-A(M2-7C10 + M2-9E3) Antibody
100uL
EUR 238.8
Description: Primary antibody against MART-1 / Melan-A(M2-7C10 + M2-9E3), CF640R conjugate, Concentration: 0.1mg/mL

M2 Polarization information

Luciferase Polyclonal Antibody
30382-100ul 100ul
EUR 302.4

Luciferase Polyclonal Antibody
30382-50ul 50ul
EUR 224.4

AAV1 Luciferase
78452 50 µl x 2
EUR 545
Description: Adeno-Associated Virus Serotype 1 (AAV1) exhibits high homology with other AAV serotypes. AAV1 efficiently transduces muscle tissue, as determined by a region of the capsid protein VP1 (amino acids 350 to 430) which functions as a major determinant of tissue tropism._x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase under the control of a CMV promoter.

AAV2 Luciferase
78453 50 µl x 2
EUR 545
Description: Adeno-Associated Virus serotype 2 (AAV2) is the best characterized AAV serotype. Nearly all recombinant AAV serotypes utilize the AAV2 inverted terminal repeats (ITRs). AAV2 requires the expression of Heparan Sulfate Proteoglycan (HSPG) on the surface of host for cells for binding and internalization. Of nearly all the discovered AAV serotypes, AAV2 has the best transduction efficiency in cell culture and is the best tool for in vitro studies._x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase under the control of a CMV promoter.

AAV3 Luciferase
78454 50 µl x 2
EUR 545
Description: Adeno-Associated Virus Serotype 3 (AAV3) shares 82% sequence homology with AAV2, and like AAV2, requires the Heparan Sulfate Proteoglycan (HSPG) receptor for cell attachment. AAV3 vectors transduce human liver cancer cells extremely efficiently because AAV3 utilizes the human Hepatocyte Growth Factor Receptor (hHGFR) as a co-receptor for viral entry, which is highly expressed in these cells. Both the extracellular and intracellular kinase domains of hHGFR are required for AAV3-mediated transgene expression._x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase gene under the control of a CMV promoter. AAV transduction efficiency can easily be verified by measurement of luciferase activity.

AAV5 Luciferase
78456 50 µl x 2
EUR 545
Description: Adeno-Associated Virus Serotype 5 (AAV5) differs from other parvovirus serotypes according to serological and DNA hybridization data, and AAV5 also uses different inverted terminal repeats (ITRs) compared to other AAV serotypes. AAV5 is the most efficient vector for transducing sensory neurons and is effective at mediating gene transfer into human and murine airway epithelia. In addition, AAV5 vectors show a higher tropism for both mouse and human dendritic cells than AAV1, AAV2, AAV7, or AAV8._x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase gene under the control of a CMV promoter. AAV transduction efficiency can easily be verified by measurement of luciferase activity.

AAV6 Luciferase
78457 50 µl x 2
EUR 545
Description: Adeno-Associated Virus serotype 6 (AAV6) appears to be related to AAV1 by sequence analysis and shows the best transduction efficiency in pancreatic beta-cells compared to other AAV serotypes. AAV6 vectors are also particularly effective in the transduction of human prostate, breast, and liver cancer cells._x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase gene under the control of a CMV promoter. AAV transduction efficiency can easily be verified by measurement of luciferase activity.

AAV8 Luciferase
78458 50 µl x 2
EUR 545
Description: Adeno-Associated Virus serotype 8 (AAV8) was isolated from rhesus monkey tissue, and the AAV8 rep and cap nucleotide sequences have 88% homology with AAV7 and 82% with AAV2. AAV8 exhibits greater transduction efficiency in the liver than other AAV serotypes. AAV8 and 9 have recently been used to correct disease-causing mutations and improve muscle function in mouse models of Duchenne muscular dystrophy._x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase gene under the control of a CMV promoter. AAV transduction efficiency can easily be verified by measurement of luciferase activity.

AAV9 Luciferase
78459 50 µl x 2
EUR 545
Description: Adeno-Associated Virus serotype 9 (AAV9) is one of the most promising serotypes for gene therapy applications. AAV9 transduces a wide range of tissue types, including cardiac and skeletal muscle, liver, pancreas, and eye tissue. AAV8 and AAV9 have recently been used to correct disease-causing mutations and improve muscle function in mouse models of Duchenne muscular dystrophy. AAV9 has significantly lower seroprevalence in the human population than other AAV serotypes, making AAV9 a desirable candidate for therapeutic applications.         _x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase gene under the control of a CMV promoter. AAV transduction efficiency can easily be verified by measurement of luciferase activity.

CFPAC-1 / Luciferase (Puro) Stable Cells
SC054-L 2 x 106 cell/ml x 1ml
EUR 1800
Description: Luciferse (firefly) expression stable cell line in CFPAC-1 cells with Puromycin resistance

Luciferase, Active
enz-1035 1µg
EUR 60
Description: Recombinant Firefly Luciferin 4-Monooxygenase, Active

Gaussia luciferase
0308-1 1 mg Ask for price

Gaussia luciferase
0308-2 300 µg Ask for price

Luciferase, firefly
HY-P1004A 5mg
EUR 555.6

Human PANC-1 / Luciferase (Puro) Cell Line
SC068-Luc 2 x 106 cell/ml x 1ml
EUR 2670
Description: Firefly luciferase expression stable cell line in Human PANC-1 cells with Puromycin resistance

IGHVII-1-1 3'UTR Luciferase Stable Cell Line
TU010728 1.0 ml
EUR 2799.6

Luciferase antibody
20R-1419 2 mL
EUR 2413.2
Description: Rabbit Polyclonal Luciferase Antibody